about
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory propertiesThe endocannabinoid system as an emerging target of pharmacotherapyThe endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungsCannabinoids attenuate norepinephrine-induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N-acetyltransferase activity without involvement of cannabinoid receptorsCB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction.Bilateral renal cortical necrosis associated with smoking synthetic cannabinoids.Cardiovascular system effects of marijuana.Alkamides activate jasmonic acid biosynthesis and signaling pathways and confer resistance to Botrytis cinerea in Arabidopsis thaliana.Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptorsBinding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells.GPR55 deletion in mice leads to age-related ventricular dysfunction and impaired adrenoceptor-mediated inotropic responses.Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.Cardiovascular consequences of marijuana use.The complexities of the cardiovascular actions of cannabinoidsCannabinoids and cancer: pros and cons of an antitumour strategy.Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities.Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusionsBlood pressure regulation by endocannabinoids and their receptorsSerum endocannabinoid content is altered in females with depressive disorders: a preliminary report.Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans.Cardiovascular pharmacology of cannabinoids.Altered cerebral blood flow and neurocognitive correlates in adolescent cannabis usersNew anti-inflammatory agents to reduce atherosclerosis.Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.Downstream effects of endocannabinoid on blood cells: implications for health and disease.Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis.Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.Effects of chronic nitric oxide synthase inhibition on the cardiovascular responses to cannabinoids in vivo and in vitro.Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study.Complex regional haemodynamic effects of anandamide in conscious rats.Cytochrome P450 pathway contributes to methanandamide-induced vasorelaxation in rat aorta.Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.Cannabinoids throw up a conundrum.Expression of functionally active cannabinoid receptor CB1 in the human prostate gland.Binding of anandamide to bovine serum albumin.Differential effects of endogenous, phyto and synthetic cannabinoids on thrombogenesis and platelet activity.The anandamide effect on NO/cGMP pathway in human platelets.Surgical considerations of marijuana use in elective procedures
P2860
Q24541462-7598B1CF-E90C-45B2-AAF9-91862D525222Q24648473-DD767513-0E82-438E-8F03-C4D263767736Q28185785-43CC73D7-131A-4BF4-80B8-14A36DC8997AQ28574512-28D0CCC2-C646-4DD6-B534-2E4D921E7F3BQ30918735-4A1633CC-2F4B-4176-ADE1-78211A056820Q33823224-A6F411E8-6CD4-4E31-A0FA-2B3E5CBB83A4Q33962206-2E1E0165-35B2-4CB3-8DEF-EF3ABDCB83EBQ34072673-95A72674-2446-44DF-BE3B-320E9DCD890EQ34098252-00C55A72-935E-45A2-82AD-EEC75E04F6D6Q34128351-C8532DF6-B4C7-43A6-90CE-4B62E34490D9Q34282113-A8BD0A30-5E36-4A52-A407-E7E3ACCEA967Q34798544-67018433-E462-452F-9D0D-1C06A774463CQ34986747-CAFA8463-4E59-4A80-80A3-1316DF6D4C3BQ35047093-732CB047-86C2-4C7E-802A-748F8036C631Q35100892-A552A84C-85B1-4D94-81A7-8A45F5896367Q35228889-7F1CF8DC-A825-413B-804D-84B205F580EFQ36052772-D870BF41-0BF1-4F14-926A-6861C64460C9Q36135785-891250A5-DC49-4377-AD4E-DE0E54A6DFABQ36174333-F19945F1-8EE6-4C68-B360-45504733044DQ36234238-88796E38-879A-4FB0-BC36-AFE42A9326D6Q36431860-44010DC2-2495-491C-A3A6-E2AE2E2D6A7EQ36433724-0298D898-4DF6-47DF-83EB-A3975DC61985Q36576558-ECC8CC40-E9DC-41F0-9123-80E475B42849Q36891652-19A12A09-3D42-4781-B383-F836DEFFE32AQ38468985-79D86FFD-5274-44EE-A943-0F3E19579046Q38684679-628A5C27-AC70-483B-B746-65808489757CQ40361574-75AF6591-D4D7-4BAF-8E47-FEA4CE8205F9Q41604550-8BC6534C-7B5B-4928-9CFB-33E1DE25C470Q41764918-7A67A712-81CD-4CC7-ADF4-135053FAFF51Q41906876-5CD1B61D-2406-495B-A2E6-E27556C1B2BEQ42111729-1F3F972A-CA91-4A41-BA80-31267709E334Q42918598-8396F07C-4CA6-4456-A9F9-9BA11D000954Q42940476-E4C8FDE1-21F2-489C-9738-7C802BAF5C05Q43263649-3451B35C-5626-4856-87FA-24485489358FQ44259374-3C1DF5BE-8343-46C0-B9FA-3438509E45B9Q44499481-6F30E682-BC1D-466E-AD12-51DF59B7D200Q53105853-39A85707-533F-471B-8978-576882CF0794Q54612198-B704A53D-7D12-4916-8568-F72A7B62B7EAQ58737504-6F56B8F9-8116-4008-9EBA-604398F3B3B4
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Endocannabinoids as cardiovascular modulators.
@ast
Endocannabinoids as cardiovascular modulators.
@en
Endocannabinoids as cardiovascular modulators.
@nl
type
label
Endocannabinoids as cardiovascular modulators.
@ast
Endocannabinoids as cardiovascular modulators.
@en
Endocannabinoids as cardiovascular modulators.
@nl
prefLabel
Endocannabinoids as cardiovascular modulators.
@ast
Endocannabinoids as cardiovascular modulators.
@en
Endocannabinoids as cardiovascular modulators.
@nl
P2093
P1476
Endocannabinoids as cardiovascular modulators.
@en
P2093
J A Wagner
S K Goparaju
P304
P356
10.1016/S0009-3084(00)00194-8
P577
2000-11-01T00:00:00Z